Comparison of Characteristics and Outcomes of Veterans With Stable Ischemic Heart Disease Enrolled in the COURAGE Trial Versus the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program
Introduction
Randomized clinical trials have not demonstrated a survival benefit for percutaneous coronary intervention (PCI) in patients with stable ischemic heart disease (SIHD).1, 2, 3 However, the applicability of clinical trials that inform the management of patients with SIHD may be limited by selection bias.4, 5, 6, 7, 8 Furthermore, participants of randomized clinical trials may represent a particularly engaged patient subset, with greater involvement in their own medical care. The large, multicenter, randomized COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial compared an initial strategy of optimal medical therapy (OMT) to an initial strategy of OMT and PCI in patients with SIHD and found no significant differences in the risk of death, myocardial infarction, or other major cardiovascular events between the 2 groups, even with up to 15 years of follow-up.9,10 A little less than half of the participants of COURAGE were enrolled and randomized at Veterans Affairs (VA) hospitals. The primary objective of this study was to evaluate the generalizability of the COURAGE trial to the broader population of veterans with SIHD referred for invasive coronary angiography.
Section snippets
Methods
The VA CART Program is a national quality improvement program supporting all VA cardiac catheterization laboratories. The CART Program is a clinical software application that collects standardized data on diagnostic and interventional cardiac procedures.11,12 These data are combined with other VA data sources to generate a longitudinal data repository. All patients who underwent diagnostic coronary angiography for SIHD between January 1, 2005, when the CART program was launched, and September
Results
Baseline characteristics of the COURAGE-eligible patients from VA CART with SIHD (n = 59,758) and participants of VA COURAGE (n = 968) are shown in Table 1. Patients from VA CART with SIHD were older, more likely to be White, and had a higher body mass index than participants of VA COURAGE. Patients from VA CART with SIHD were more likely to have diabetes mellitus, hypertension, pulmonary disease, previous coronary revascularization with PCI or CABG, and lower glomerular filtration rates than
Discussion
In this comparison of patients from VA CART with SIHD who received routine clinical care after coronary angiography and veterans enrolled in the COURAGE trial, real-world patients were older, more likely to have traditional cardiovascular risk factors, pulmonary and renal disease, previously revascularized coronary artery disease, more favorable lipid profiles, and less extensive coronary artery disease than trial participants. At baseline and at 1 year after the index coronary angiogram,
Disclosures
Dr. Smilowitz serves on an advisory board for Abbott Vascular. Dr. Shah serves on an advisory board for Philips Volcano and Terumo Medical. The remaining authors have no conflicts of interest to declare.
Acknowledgment
The authors dedicate this manuscript to the memory of Steven P. Sedlis, a Professor of Medicine, consummate mentor, and dedicated physician, who devoted his career to improving patient outcomes, educating the next generation of physicians, and advancing science.
References (30)
External validity of randomised controlled trials: "to whom do the results of this trial apply?
Lancet
(2005)- et al.
Data quality of an electronic health record tool to support VA cardiac catheterization laboratory quality improvement: the VA Clinical Assessment, Reporting, and Tracking System for Cath Labs (CART) program
Am Heart J
(2013) - et al.
A national clinical quality program for Veterans Affairs catheterization laboratories (from the Veterans Affairs clinical assessment, reporting, and tracking program)
Am J Cardiol
(2014) - et al.
COURAGE trial coprincipal investigators and study coordinators. Design and rationale of the Clinical Outcomes Utilizing revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424
Am Heart J
(2006) - et al.
COURAGE Trial Investigators. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial)
Am J Cardiol
(2009) - et al.
Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing revascularization and Aggressive Drug Evaluation) trial
J Am Coll Cardiol
(2010) - et al.
SYNTAX Extended Survival Investigators. Impact of optimal medical therapy on 10-year mortality after coronary revascularization
J Am Coll Cardiol
(2021) - et al.
Defining the proper SYNTAX for long-term benefit of myocardial revascularization with optimal medical therapy
J Am Coll Cardiol
(2021) - et al.
International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: rationale and design
Am Heart J
(2018) - et al.
Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention
Am Heart J
(2012)
2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Circulation
ACCF/SCAI/STS/AATS/AHA/ASNC 2009 appropriateness criteria for coronary revascularization: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography
Circulation
Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials
JAMA Intern Med
Commentary: how the debate about comparative effectiveness research should impact the future of clinical trials
Stat Med
Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change
Ann Intern Med
Cited by (0)
Dr. Shah was supported, in part, by the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development, Washington, District of Columbia, iK2CX001074 and the National Heart, Lung, and Blood Institute of the National Institutes of Health, Bethesda, Maryland, R01HL146206. Dr. Smilowitz is supported, in part, by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number K23HL150315.